Douglas Tsao
Stock Analyst at H.C. Wainwright
(4.94)
# 162
Out of 4,673 analysts
1253
Total ratings
58.3%
Success rate
28%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Reiterated: Buy | $940 → $1,202 | $1,039.78 | +15.60% | 68 | Aug 18, 2026 | |
| NMRA Neumora Therapeutics | Reiterated: Buy | $7 | $1.63 | +329.45% | 25 | Aug 18, 2026 | |
| RAPP Rapport Therapeutics | Reiterated: Buy | $66 | $48.24 | +36.82% | 13 | Aug 17, 2026 | |
| DARE Daré Bioscience | Reiterated: Buy | $12 | $0.8199 | +1,363.59% | 41 | Aug 14, 2026 | |
| AEON AEON Biopharma | Maintained: Buy | $360 → $1.2 | $0.1921 | +524.67% | 10 | Aug 14, 2026 | |
| BHVN Biohaven | Maintained: Hold | $10 | $13.85 | -27.80% | 22 | Aug 13, 2026 | |
| TBPH Theravance Biopharma | Maintained: Hold | $17 | $17.01 | -0.06% | 41 | Aug 11, 2026 | |
| CRNX Crinetics Pharmaceuticals | Reiterated: Hold | $85 | $84.69 | +0.37% | 65 | Aug 11, 2026 | |
| NERV Minerva Neurosciences | Reiterated: Hold | $7 | $4.84 | +44.63% | 44 | Aug 10, 2026 | |
| XENE Xenon Pharmaceuticals | Reiterated: Buy | $74 | $60.77 | +21.77% | 17 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $117 → $167 | $154.32 | +8.22% | 79 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 → $41 | $44.37 | -7.60% | 46 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $25.08 | +35.57% | 20 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 | $79.81 | +50.36% | 39 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1,201 | $375.94 | +219.47% | 56 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $24.29 | -9.43% | 31 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 → $41 | $36.30 | +12.95% | 46 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.42 | +392.96% | 78 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $24.67 | +54.03% | 30 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $43 | $48.33 | -11.03% | 60 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $5.09 | -1.77% | 46 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $0.5 → $1.6 | $0.6472 | +147.22% | 48 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | kr 103.00 | kr 41.74 | +146.77% | 52 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.13 | - | 50 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $8.39 | +54.95% | 56 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.93 | +262.69% | 13 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $125 → $5 | $0.001 | n/a | 26 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 → $3 | $0.000001 | n/a | 13 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 | $17.28 | n/a | 4 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.06 | n/a | 19 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €19.00 → €11.00 | €4.17 | n/a | 7 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $23 | $37.34 | n/a | 12 | Aug 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $31 → $33 | $36.32 | n/a | 2 | Jul 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $93 → $80 | $14.25 | n/a | 8 | Jun 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $8.82 | n/a | 17 | Jun 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $17.91 | n/a | 2 | May 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $71 → $77 | $77.73 | n/a | 6 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $108 → $120 | $172.23 | n/a | 12 | Oct 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 → $120 | $259.82 | n/a | 3 | Oct 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $108.17 | n/a | 3 | Jun 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $47 → $50 | $16.32 | n/a | 6 | May 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $200 | $254.28 | n/a | 7 | Jan 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $295.19 | n/a | 5 | Nov 30, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $14 → $2 | $13.45 | n/a | 5 | Nov 16, 2016 |
argenx SE
Aug 18, 2026
Reiterated: Buy
Price Target: $940 → $1,202
Current: $1,039.78
Upside: +15.60%
Neumora Therapeutics
Aug 18, 2026
Reiterated: Buy
Price Target: $7
Current: $1.63
Upside: +329.45%
Rapport Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $66
Current: $48.24
Upside: +36.82%
Daré Bioscience
Aug 14, 2026
Reiterated: Buy
Price Target: $12
Current: $0.8199
Upside: +1,363.59%
AEON Biopharma
Aug 14, 2026
Maintained: Buy
Price Target: $360 → $1.2
Current: $0.1921
Upside: +524.67%
Biohaven
Aug 13, 2026
Maintained: Hold
Price Target: $10
Current: $13.85
Upside: -27.80%
Theravance Biopharma
Aug 11, 2026
Maintained: Hold
Price Target: $17
Current: $17.01
Upside: -0.06%
Crinetics Pharmaceuticals
Aug 11, 2026
Reiterated: Hold
Price Target: $85
Current: $84.69
Upside: +0.37%
Minerva Neurosciences
Aug 10, 2026
Reiterated: Hold
Price Target: $7
Current: $4.84
Upside: +44.63%
Xenon Pharmaceuticals
Aug 10, 2026
Reiterated: Buy
Price Target: $74
Current: $60.77
Upside: +21.77%
Aug 10, 2026
Reiterated: Buy
Price Target: $117 → $167
Current: $154.32
Upside: +8.22%
Aug 10, 2026
Reiterated: Buy
Price Target: $40 → $41
Current: $44.37
Upside: -7.60%
Aug 10, 2026
Reiterated: Buy
Price Target: $34
Current: $25.08
Upside: +35.57%
Aug 10, 2026
Reiterated: Buy
Price Target: $120
Current: $79.81
Upside: +50.36%
Aug 10, 2026
Reiterated: Buy
Price Target: $1,201
Current: $375.94
Upside: +219.47%
Aug 7, 2026
Reiterated: Buy
Price Target: $22
Current: $24.29
Upside: -9.43%
Aug 7, 2026
Reiterated: Buy
Price Target: $34 → $41
Current: $36.30
Upside: +12.95%
Aug 6, 2026
Reiterated: Buy
Price Target: $7
Current: $1.42
Upside: +392.96%
Aug 5, 2026
Reiterated: Buy
Price Target: $38
Current: $24.67
Upside: +54.03%
Jul 29, 2026
Reiterated: Hold
Price Target: $43
Current: $48.33
Upside: -11.03%
Jul 29, 2026
Reiterated: Buy
Price Target: $5
Current: $5.09
Upside: -1.77%
Jul 28, 2026
Rated: Hold
Price Target: $0.5 → $1.6
Current: $0.6472
Upside: +147.22%
Jul 24, 2026
Reiterated: Buy
Price Target: kr 103.00
Current: kr 41.74
Upside: +146.77%
Jun 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.13
Upside: -
May 5, 2026
Maintained: Buy
Price Target: $13
Current: $8.39
Upside: +54.95%
Nov 6, 2025
Reiterated: Buy
Price Target: $7
Current: $1.93
Upside: +262.69%
Nov 14, 2024
Downgraded: Hold
Price Target: $125 → $5
Current: $0.001
Upside: n/a
Aug 21, 2023
Reiterated: Buy
Price Target: $4 → $3
Current: $0.000001
Upside: n/a
Mar 8, 2023
Maintained: Hold
Price Target: $6
Current: $17.28
Upside: n/a
Nov 30, 2022
Rated: Hold
Price Target: n/a
Current: $2.06
Upside: n/a
Nov 1, 2022
Reiterated: Buy
Price Target: €19.00 → €11.00
Current: €4.17
Upside: n/a
Aug 6, 2018
Maintained: Hold
Price Target: $23
Current: $37.34
Upside: n/a
Jul 3, 2018
Maintained: Sell
Price Target: $31 → $33
Current: $36.32
Upside: n/a
Jun 6, 2018
Downgraded: Hold
Price Target: $93 → $80
Current: $14.25
Upside: n/a
Jun 6, 2018
Upgraded: Buy
Price Target: n/a
Current: $8.82
Upside: n/a
May 1, 2018
Initiated Coverage: Buy
Price Target: $27
Current: $17.91
Upside: n/a
Feb 16, 2018
Maintained: Hold
Price Target: $71 → $77
Current: $77.73
Upside: n/a
Oct 27, 2017
Maintained: Hold
Price Target: $108 → $120
Current: $172.23
Upside: n/a
Oct 27, 2017
Reiterated: Buy
Price Target: $100 → $120
Current: $259.82
Upside: n/a
Jun 22, 2017
Maintained: Buy
Price Target: $16
Current: $108.17
Upside: n/a
May 22, 2017
Upgraded: Buy
Price Target: $47 → $50
Current: $16.32
Upside: n/a
Jan 18, 2017
Maintained: Buy
Price Target: $200
Current: $254.28
Upside: n/a
Nov 30, 2016
Upgraded: Hold
Price Target: n/a
Current: $295.19
Upside: n/a
Nov 16, 2016
Reiterated: Sell
Price Target: $14 → $2
Current: $13.45
Upside: n/a